Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells

Cell Biology and Toxicology

Volumn 20, Issue 5, 2004, Pages 261-271

  Ozkan, A ^a   Ayhan, A ^a   Fiskin, K ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Cytotoxicity; Epirubicin; LAK; MCF 7 cells; Reactive oxygen species

Indexed keywords

EPIRUBICIN; GLUTATHIONE PEROXIDASE; GLYCOPROTEIN P; HYDROXYL RADICAL; OXYGEN RADICAL; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERANCE; EFFECTOR CELL; HUMAN; HUMAN CELL; IC 50; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; WILD TYPE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EPIRUBICIN; FEMALE; FREE RADICALS; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; P-GLYCOPROTEIN;

MINK CELL FOCUS-FORMING VIRUS;

EID: 17644373821     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-004-3471-6     Document Type: Article

References (53)

1. Azzi S, Montecucco C, Richter C. The use of acetylated ferricytochrome c for the detection of superoxide radicals produced in biological membranes. Biochem Biophys Res Commun. 1975;65:597-603.
2. Bachur NR, Gee MV, Friedman RD. Nuclear-catalysed antibiotic free radical formation. Cancer Res. 1982;42:1078-81.
3. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986;261:15544-9.
4. Bradford MM. A rapid and sensitive method for the quantisation of microgram quantities of protein utilising the principle of protein dye binding. Anal Biochem. 1976;72:248-54.
5. Chen R, Pan L, Zhou S. Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3. Zhonghua Fu Chan Ke Za Zhi. 1999;34:172-4.
6. Dierickx PJ. Glutathione-dependent cytotoxicity of the chloroacetanilide herbicides alachlor, metolachor, and propachlor in rat and human hepatoma-derived cultured cells. Cell Biol Toxicol. 1999;15:325-32.
7. Dobbs NA, Twelwes CJ, Rizzi P, et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chem Pharm. 1994;34:405-10.
8. Duncan DB. Multiple range and multiple F test. Biometrics. 1955;11:1-14.
9. Ellman GL. Tissue sulfhydril groups. Arch Biochem Biophys. 1959;82:70-7.
10. Furusawa S, Nakana S, Wada M, et al. Augmentation of epirubicin cytotoxicity by cycloheximide. Res Commun Mol Path Pharm. 1996;91:245-52.
11. Goldstein LJ, Galski H, Fajo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989;81:116-24.
12. Gram TE, Litterst CL, Mimnaugh EG. Enzymatic conjugation of foreign chemical compounds by rabbit lung and liver. Drug Metab Dispos. 1974;2:254-8.
13. Grimm E. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823-41.
14. Grunberg E, Eckert K, Maurer HR. Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro. Int J Oncol. 1998;12:957-63.
15. Habig WH, Jakoby WB. Assay for differentiation of glutathione 5-transferases. Methods Enzymol. 1974;77:398-405.
16. Hall KS, Endresen L, Huitfeldt, HS, Rugstad HE. Induction of in vitro resistance to 4′-epidoxorubicin and cis-dichlorodiammineplatinum in hepatoma cells. Anticancer Res. 1991;11:817-24.
17. Hussain RF, Nouri AME, Oliver, RTD. A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods. 1993;160:89-95.
18. Jansson Ö, Motlagh PB, Persson M, Henrikson R, Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999;58:1801-6.
19. Julicher RHM, Sterremberg L, Bast A, Riksen ROWM, Koomen JM, Nordhoek J. The role of lipid peroxidation in acute doxorubicin induced cardiotoxicity as studied in rat isolated heart. J Pharm Pharmacol. 1986;38:277-82.
20. Kappus H. Overwiev of enzyme system involved in bioreduction of drugs and in redox cycling. Biochem Pharmacol. 1986;35:419-25.
21. Kinnula K, Linnaynma K, Rayvyo KO, Kinnula VL. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br J Cancer. 1998;77:1097-20.
22. Komatsu F, Ishiguro K. Lymphokine-activated killer cells can kill target cells not only early killing but also by late killing, and the late killing level against autotumor cell line. Oncol Res. 2003;13:235-41.
23. Kotoh S, Naito S, Yokoniza A, et al. Inversed expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res. 1994;54:3248-52.
24. Kwak JY, Han MK, Choy KS, et al. Cytokines secreted by lymhokine-activated killer cells induced endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol. 2000;203:84-94.
25. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium deficient rat liver. Biochem Biophys Res Commun. 1976;71:952-8.
26. Leontieva OV, Preobrazhenskaya MN, Bernacki RJ. Partial circumvention of P-glycoprotein-mediated multidrug-resistance by doxorubicin-14-O-hemiadipe. Invest New Drugs. 2002;20:35-48.
27. Luck H. Catalase. In: HU Bergmeyer, editor. Methods of enzymatic analayses. New York: Verlag Chemie Academic Press, 1963:885-94.
28. Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces Fas expression in oesophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology. 2000;59:336-43.
29. McCord JM, Fridovich IJ. Preparation and assays of superoxide dismutase. Biol Chem. 1969;244:6049-55.
30. Mimnaugh EG, Dusre L, Atwell J, Myers CE. Differential oxygen radical susceptibility of adriamycin-sensitive and resistant MCF-7 human breast tumor cells. Cancer Res. 1989;49:8-15.
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
32. Okamoto M, Kasetani H, Kaji R, et al. cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother. 1998;4:233-41.
33. Ozkan A, Fiskin K. Epirubicin cytotoxicity in non-small cell lung cancer (NSCLC) cells. Turkish J Hematol Oncol. 2003;13:125-33.
34. Ozkan A, Fiskin K. Cytotoxicity of low dose epirubicin combined with lymphokine activated killer cells against hepatocellular carcinoma cell line Hepatoma G2 (In press).
35. Ozkan A, Fiskin K. Free oxygen radicals, carcinogenesis and antioxidant enzymes (In press).
36. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterisation of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158-69.
37. Pavarov LS, Leontieva OV, Preobrazhenskaya MN. partial circumvention of P-glycoprotein (Pgp)-associated resistance to doxorubicin (Dox) in MCF7/R human breast carcinoma and P388/R murine leukemia cell lines by doxorubicin-14-O- hemiadipate (H-Dox). Russian J Bioorg Chem 1995;21:797-803.
38. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986;164:814-19.
39. Pross HF, Lotzova E. Role of natural killer cells in cancer. Nat Immun. 1993;12:279-92.
40. Ribeiro-Dias F, Barbuto JAM, Tsujita M, Jancar S. Discrimination between NK and LAK cytotoxicity activities of murine spleen cells by MTT assay: differential inhibition by PGE2 and EDTA. J Immun Meth. 2000;241:121-9.
41. Rihova B, Strohalm J, Kubackova K. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J Control Release. 2002;17:97-114.
42. Runge D, Köhler C, Kostrubsky EV, et al. Reduction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypic reducers in human hepatocytes. Biochem Bioph Res Commun. 2000;27 333-41.
43. Savas B, Cole PC, Tsuruo T, Pross HF. P-Glycoproteinmediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma. J Clin Immunol. 1996;16:348-57.
44. Savas B, Kerr PE, Ustun H, Cole SPC, Pross HF. Lymphokineactivated killer cell susceptibility and multidrug resistance in small cell lung carcinoma. Anticancer Res. 1998;18:4355-62.
45. Siegsmund MJ, Steidler A, Kreukler C, Köhrmann KU, Alken P. Enhanced in vitro cytotoxicity of Idarubicin in rat prostate carcinoma cells. Eur Urol. 1997;31:365-70.
46. Sinha BK, Katki AG, Batists G, Cowan KH, Myers CH. Differential formation of hydroxyl radical by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochem. 1987;26:3776-81.
47. Snedocor GW, Cochran WG. Statistical methods, 6th edn. Ames, IA: Iowa State University Press; 1967:21-35.
48. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection hepatocellular carcinoma - a literature review of randomised control trials. World J Gastroenterol. 2003;9:635-40.
49. Synder HS, Bredt DS. Biological roles of nitric oxide. Sci Am. 1992;5:28-34.
50. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-92.
51. Williams CH, Kamin H. Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem. 1962;237:587-95.
52. Wolfram ES, Ryan P, Salvatore C, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med. 2003;9:750-5.
53. Yamamota T, Yoneda K, Ueta E, Doi S, Osaki T. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur J Cancer. 2000;36:2007-17.